NCT04578171 Residual Exacerbations With Mepolizumab
| NCT ID | NCT04578171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Laval University |
| Condition | Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2021-07-06 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2021-07-06 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Eligibility Criteria
Inclusion Criteria: * With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society * Eligible for mepolizumab treatment * Able and willing to sign the informed consent form Exclusion Criteria: * Any respiratory disease apart from asthma * Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
Contact & Investigator
Andréanne Côté, MD
PRINCIPAL INVESTIGATOR
IUCPQ-UL
Frequently Asked Questions
Who can join the NCT04578171 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04578171 currently recruiting?
Yes, NCT04578171 is actively recruiting participants. Contact the research team at marie-eve.boulay@criucpq.ulaval.ca for enrollment information.
Where is the NCT04578171 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT04578171 clinical trial?
NCT04578171 is sponsored by Laval University. The principal investigator is Andréanne Côté, MD at IUCPQ-UL. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.